Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CelcuityFRA:7VR 18 Cash Ratio is 11.65 as of Mar. 2026, which is 40% below its 10-year median of 19.48. GuruFocus rates FRA:7VR with a GF Score™ of 18/100. The stock has 2 warning signs investors should review. Among 1,381 Biotechnology companies, Celcuity ranks better than 83.71% on this metric.
Celcuity has a Cash Ratio of 11.65. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Celcuity's Cash Ratio or its related term are showing as below:
FRA:7VR'
s Cash Ratio Range Over the Past 10 Years
Min: 4.22 Med: 19.48 Max: 96.87
Current: 11.65
During the past 11 years, Celcuity's highest Cash Ratio was 96.87. The lowest was 4.22. And the median was 19.48.
FRA:7VR's Cash Ratio is ranked better than 83.71% of 1381
companies
in the Biotechnology industry
Industry Median: 2.95
vs FRA:7VR: 11.65
Celcuity (FRA:7VR) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Celcuity Cash Ratio Related Terms
Celcuity Cash Ratio Historical Data
* Premium members only.
The historical data trend for Celcuity's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Celcuity's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celcuity Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celcuity's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Celcuity's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celcuity (FRA:7VR) has a Cash Ratio of 11.65 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Celcuity and its competitors. This is 40% below median its historical median of 19.48. Over the past decade, Celcuity's Cash Ratio has ranged from 4.22 to 96.87. According to the industry distribution chart, Celcuity ranks #225 out of 1381 companies in the Biotechnology industry, placing it in the top 16.3%.
Is Celcuity's Cash Ratio too high?
Celcuity's current Cash Ratio of 11.65 is 40% below median its 10-year median of 19.48. Over the past 10 years, this metric has ranged from a low of 4.22 to a high of 96.87. The Biotechnology industry median Cash Ratio is 2.95. Celcuity's value of 11.65 is 294.9% above this industry median. Based on the distribution chart, Celcuity ranks #225 out of 1381 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Celcuity has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Celcuity's Cash Ratio compare to RLAY and VKTX?
According to the Biotechnology industry distribution chart, Celcuity ranks #225 out of 1381 companies for Cash Ratio. This places Celcuity in the top 16% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.95. Celcuity's value of 11.65 is 294.9% above this benchmark. Historically, Celcuity's own Cash Ratio has ranged from 4.22 to 96.87 over the past decade. While the company's 10-year median is 19.48 vs. the industry median of 2.95, Celcuity has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.95, based on 1,381 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celcuity's current Cash Ratio of 11.65 is 294.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Celcuity and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celcuity's current Cash Ratio is 11.65, which is 40% below median its own 10-year median of 19.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celcuity stock overvalued right now?
Celcuity (FRA:7VR) has a current Cash Ratio of 11.65. The current Cash Ratio is 11.65, which is 40% below median its 10-year median of 19.48 and 294.9% above the Biotechnology industry median of 2.95. Celcuity's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Celcuity (FRA:7VR), the current Cash Ratio is 11.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
18GF Score
Get the complete analysis for FRA:7VR
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7VR has been successfully added to your 
